La vendita allo scoperto per Bausch Health Companies dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Bausch Health Companies. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Bausch Health Companies (NYSE:BHC) Azioni, Report sulle vendite allo scoperto

Bausch Health Companies

Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Cos

Bausch Health Companies Inc. Common Stock

Bausch Health Companies Inc

BillionHappiness

BENCHMARK HLDGS PLC by Benchmark Hldgs PLC

Benchmark Holdings PLC

<p><strong>D-Wave Quantum Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>), <strong>Quantum Computing Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NYSE">QUBT</a>) and <strong>IonQ, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares are soaring on Monday. Here&#8217;s what <a href="https://www.benzinga.com//node/41984578">you need to know</a>.</p>
<p><strong>What To Know:</strong> Amazon Web Services announced the Quantum Embark Program, which builds on Amazon Bracket.</p>
<p>The program consists of three service offerings. The Use Case Discovery helps customers identify potential business applications for quantum computing. The Technical Enablement workshop provides in-depth knowledge and hands-on experience with quantum computing. Finally, the Deep Dive program focuses on exploring specific quantum computing applications.</p>
<p>Stocks in the quantum industry may be moving higher following Amazon Web Services&#8217; announcement as the expanded program helps businesses understand how quantum computing can address their problems, potentially driving up demand for quantum solutions.</p>
<p>Last week, IonQ <a href="https://www.benzinga.com//node/42047774">showcased</a> a hybrid quantum computing workflow combining its quantum hardware with <strong>NVIDIA Inc.</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CUDA-Q platform. Additionally, several technology stocks across various sectors rose following <strong>Snowflake Inc.</strong>&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) better-than-expected third-quarter earnings for 2024.</p>
<p>Quantum stocks are buzzing on social media Monday morning. Quantum Computing shares have surged over 235%, D-Wave is up 115% and IonQ has climbed 28% in the past week. </p>
<p><strong>Related Link: <a href="https://www.benzinga.com/markets/equities/24/11/42153356/is-warren-buffett-preparing-for-a-market-downturn-with-berkshire-hathaways-325b-cash-pile-analys">Is Warren Buffett Preparing For A Market Downturn With Berkshire Hathaway&#8217;s $325B Cash Pile? Analyst Says Internet Bubble And 2008 Crash May Have Lessons</a></strong></p>
<p><strong>Price Action:</strong> At the time of publication, D-Wave Quantum shares are moving 10.1% higher at $3.23, Quantum Computing stock is trading 35.3% higher at $8.3, IonQ stock is moving 3.57% higher at $32.96, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: Courtesy of IonQ, Inc.</em></p>


News

Movers

IONQ

NVDA

QBTS

QUBT

SNOW

Quantum Industry Stocks Soar: What's Behind the D-Wave, Quantum Computing and IonQ Gains?

<p>Good Morning Traders! In today&#39;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.</p>
<p>Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.</p>
<p>We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#39;s pulse to optimize your trading gains. Now, let&#39;s dive into the stock analysis:</p>
<h3><strong>SPDR S&amp;P 500 ETF Trust</strong></h3>
<p>The SPY (ARCA: SPY)&nbsp;is trading near our pivotal level of 598.04. For bullish momentum to take hold, we need to see a move above 599.24 with conviction. If buyers dominate at this level, we anticipate an upward drive to 600.51, which should act as a robust support level. Holding above 600.51 could ignite a further rally toward 604.45. In an optimistic scenario, strong demand may propel the price to our high bull target of 607.55 for the day.</p>
<p>Should 598.04 fail to hold as support, bearish momentum is expected to take over. Sellers will likely test 596.57, a crucial level to watch. A breach here could expose 593.73 to increased downside pressure. Should selling intensify further, we foresee a drop toward 592.00. If significant sell-side volume persists, our low bear target for SPY sits at 589.71.</p>
<h3><strong>Invesco QQQ Trust Series 1</strong></h3>
<p>The QQQ (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>) is currently hovering around 508.22, a key battleground for market participants. Bulls will aim to secure this level as support to drive prices upward. A hold above 508.22 could set the stage for a climb to 509.87. Continued strength would bring 511.53 into focus, and if the buying momentum accelerates, we could see a push toward 513.64. The high bull target for today stands at 515.00, provided bulls maintain control.</p>
<p>Conversely, a failure to sustain 508.22 could pave the way for bearish pressure to build. Bears would likely push the price down to 506.68. A breach here could lead to further downside exploration at 504.44. If sellers remain in control, the next significant test lies at 502.65. Failing this level, the QQQ may move toward the low bear target of 501.07.</p>
<h3><strong>Apple Inc.</strong></h3>
<p>Apple&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) is consolidating near 230.25, a critical level for the day. Bulls will need to hold this level as support to propel the stock higher. If the price maintains strength above 230.25, we anticipate a rally to 231.76. Further bullish energy could see the stock targeting 233.28, with a potential extension to our high bull target at 234.20 if buyers dominate the session.</p>
<p>However, if 230.25 cannot hold during regular trading hours, bearish momentum is expected to emerge. Sellers could drive the price lower to test 229.03. Should selling intensify, the next downside targets are 227.82 and 226.90. A breakdown at 226.90 would likely bring the price closer to the low bear target for the day at 226.08.</p>
<h3><strong>Microsoft Corp. </strong></h3>
<p>Microsoft (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) is trading near the important level of 417.25. For bulls to maintain control, this level needs to act as solid support. A sustained move above 417.25 could lead to a test of 419.17. If this level holds as support, further upward momentum could take the stock to 420.26. Continued buying pressure may drive the price to our high bull target of 421.62.</p>
<p>On the other hand, if 417.25 is breached, sellers are likely to gain the upper hand. Bears may push the price down to 416.32 initially. A break below this level would open the door to a test of 414.56. If downward pressure continues, the next significant level is 413.14, with the low bear target resting at 411.72.</p>
<h3><strong>NVIDIA Corporation</strong></h3>
<p>NVIDIA&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) is auctioning close to 142.35, a critical pivot point for the session. Bulls will aim to push the price toward 144.21 and establish it as a support level. If successful, further buying strength could drive the stock to 145.61. A strong rally could see the price testing 147.06, with 148.52 as the high bull target for the day.</p>
<p>If 142.35 cannot hold, bearish activity is likely to intensify. The first key level for the bears is 141.21. A break below this level may lead to additional selling pressure toward 140.28. Should weakness persist, a test of 139.42 could be in play, with the low bear target at 138.55.</p>
<h3><strong>Alphabet Inc Class A</strong></h3>
<p>Alphabet&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) is trading near the level of 165.41, which bulls need to defend to maintain upward momentum. If this level holds as support, we anticipate a move to 167.04. Further buying could drive the auction to test 169.34, which is our high bull target for the day.</p>
<p>If the auction fails to sustain above 165.41, bears may take control. The first downside target is 163.79. If selling accelerates, the stock could revisit 161.79. With persistent selling, the price may drop toward the low bear target of 160.36.</p>
<h3><strong>Meta Platforms Inc</strong></h3>
<p>Meta&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) is currently testing the level of 559.29, which is crucial for bulls to hold. If support is confirmed here, we expect a rally to 565.53. Sustained buying could bring 573.25 into play, and a continuation of bullish momentum might push the price to the high bull target of 580.17.</p>
<p>Should 559.29 fail as support, bearish momentum is likely to increase. Sellers may target 553.05 as the first downside level. Continued selling pressure could drive the stock to 548.44, and if this level is breached, we anticipate a move to the low bear target at 541.79.</p>
<h3><strong>Tesla Inc.</strong></h3>
<p>Tesla&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) is trading near a pivotal level at 356.80, where bulls will aim to gain control. A move above this level could initiate a rally to 363.84. Continued bullish momentum may lead to a test of 370.22, with potential for an extended push to 384.07. If buyers remain dominant, the high bull target is 390.23.</p>
<p>However, if the auction struggles to maintain 356.80 as support, bears are likely to take charge. The first target for the downside is 350.87, with further selling pressure potentially driving the price to 346.64. A breakdown below this level could lead to a test of the low bear target at 340.97.</p>
<p>Final Word:&nbsp; As we enter a holiday-shortened trading week, today&#39;s focus will be on economic updates and potential market drivers. At 10:00 AM ET, the Dallas Fed Manufacturing Index for November will be released, offering insights into regional economic activity. Later in the day, the Treasury&#39;s 2-Year Note Auction at 1:00 PM ET will be closely watched for implications on interest rates and market liquidity.</p>
<p>This week&#39;s tone may also be shaped by the selection of Scott Bessent as Treasury Secretary. His anticipated conservative policies and focus on tax reduction could influence investor sentiment. Market participants should be prepared for potential fluctuations in price, volume, and volatility due to the shortened week. Remember to adapt strategies to the evolving conditions and stay disciplined in managing risk. Trade wisely, and best of luck in today&rsquo;s session!</p>
<p>The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.</p>
<p>Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day&mdash;hours before it&#39;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.</p>
<p>For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.</p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.</em></p>


Markets

Trading Ideas

General

AAPL

GOOGL

MSFT

TSLA

Market Clubhouse Morning Memo - November 25th, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META And TSLA)

<p>Wolfe Research  analyst Brad Hewitt   initiates coverage on SPX Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) with a Outperform rating and announces Price Target of $199.</p>


Price Target

Initiation

Analyst Ratings

SPXC

Wolfe Research Initiates Coverage On SPX Techs with Outperform Rating, Announces Price Target of $199

<p>On Monday, <strong>Merck&nbsp;&amp; Co Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42159674/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevair-sotatercept-csrk-met-primary-end" rel="noreferrer noopener">high risk of mortality</a>.</p>
<p>PAH is high blood pressure in pulmonary arteries, which carry oxygen-poor blood from the heart to the lungs.</p>
<p>ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥ 24 hours).</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41693101/mercks-gardasil-shot-challenges-to-continue-analysts-optimistic-for-newly-approved-" rel="noreferrer noopener">Merck&#8217;s Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease</a></strong></p>
<p>In the study, Winrevair demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, on top of background PAH therapy.</p>
<p>An independent data monitoring committee has recommended that ZENITH be stopped early and that all participants be offered the opportunity to receive Winrevair through the SOTERIA open-label extension study.</p>
<p>In the preliminary assessment, adverse events and serious adverse events were balanced between the treatment groups.</p>
<p>Winrevair is currently approved in the U.S. and 36 countries based on the Phase 3 STELLAR trial results.</p>
<p>In March, the FDA approved Winrevair for injection for adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37966217/the-most-important-catalyst-for-mercks-stock-in-2024-could-be-sotatercept-launch-an" rel="noreferrer noopener">clinical worsening events</a>.&nbsp;</p>
<p>Most recently, in November of this year, WINREVAIR was submitted for approval in Japan based on the STELLAR trial and results from an open-label Phase 3 study in Japanese patients.</p>
<p><strong>Price Action: </strong>MRK stock is up 1.93% at $101.09&nbsp;at last check Monday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42168608/nvidias-fugatto-new-ai-model-lets-you-create-sounds-never-heard-before" target="_blank" rel="noreferrer noopener">Nvidia Unveils Fugatto: AI Tool That Transforms Sound Creation For Music, Ads, And Gaming</a></strong></li>
</ul>
<p><em>Image via Pixabay.</em></p>


Biotech

Equities

Large Cap

Health Care

Why Is Merck Stock Trading Higher On Monday?

<p>Susquehanna  analyst Shyam Patil   downgrades Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) from Positive to Neutral and lowers the price target from $105 to $85.</p>


Downgrades

BIDU

Susquehanna Downgrades Baidu to Neutral, Lowers Price Target to $85

<p>12 analysts have expressed a variety of opinions on Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $248.58, a high estimate of $285.00, and a low estimate of $211.00. This upward trend is evident, with the current average reflecting a 3.65% increase from the previous average price target of $239.83.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732554065_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Universal Health Servs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Frank Morgan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$211.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$271.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$283.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$222.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$274.00</td>
<td>$236.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Universal Health Servs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Universal Health Servs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Universal Health Servs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Universal Health Servs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UHS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Universal Health Servs analyst ratings.</strong></a></p>
<h2>All You Need to Know About Universal Health Servs</h2>
<p>Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.</p>
<h3>Universal Health Servs's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Universal Health Servs displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>11.23%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Universal Health Servs's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.53%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Universal Health Servs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.95%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Universal Health Servs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.82%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Universal Health Servs's debt-to-equity ratio is below the industry average. With a ratio of <b>0.77</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 12 Analyst Evaluations For Universal Health Servs

WIIM

TMHC

Shares of homebuilders and housing-linked stocks are trading higher amid a drop in yields.

<p>In the last three months, 5 analysts have published ratings on Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $6.8, a high estimate of $7.70, and a low estimate of $5.00. This current average reflects an increase of 25.69% from the previous average price target of $5.41. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732554055_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Latham Group's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.70</td>
<td>$7.00</td>
</tr>
<tr>
<td>Susan Maklari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$5.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$7.50</td>
<td>$5.50</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.00</td>
<td>$6.80</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.80</td>
<td>$4.75</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Latham Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Latham Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Latham Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Latham Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SWIM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Latham Group analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Latham Group</h2>
<p>Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.</p>
<h3>Understanding the Numbers: Latham Group's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Latham Group's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-6.4%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Latham Group's net margin excels beyond industry benchmarks, reaching <strong>3.92%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.43%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.7%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Latham Group's debt-to-equity ratio surpasses industry norms, standing at <strong>0.75</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SWIM

A Closer Look at 5 Analyst Recommendations For Latham Group

<p>In the latest quarter, 13 analysts provided ratings for Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $44.15, a high estimate of $50.00, and a low estimate of $40.00. Surpassing the previous average price target of $42.69, the current average has increased by 3.42%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732554042_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of Baker Hughes by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$48.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Phillip Jungwirth</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Baker Hughes. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Baker Hughes compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Baker Hughes's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Baker Hughes's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BKR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Baker Hughes analyst ratings.</strong></a></p>
<h2>Get to Know Baker Hughes Better</h2>
<p>Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. It maintains modest exposure to offshore oil and gas production. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with a high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.</p>
<h3>Breaking Down Baker Hughes's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Baker Hughes showcased positive performance, achieving a revenue growth rate of <strong>4.02%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Baker Hughes's net margin excels beyond industry benchmarks, reaching <strong>11.09%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Baker Hughes's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.82%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Baker Hughes's ROA excels beyond industry benchmarks, reaching <strong>2.07%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.37</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 13 Analyst Recommendations For Baker Hughes

<p>Financial giants have made a conspicuous bullish move on C3.ai. Our analysis of options history for C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) revealed 22 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $307,758, and 16 were calls, valued at $873,710.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $55.0 for C3.ai over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for C3.ai's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across C3.ai's significant trades, within a strike price range of $10.0 to $55.0, over the past month.</p>
<h3>C3.ai Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732554035_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.14</td>
<td>$1.87</td>
<td>$1.9</td>
<td>$50.00</td>
<td>$152.0K</td>
<td>6.6K</td>
<td align="right">856</td>
</tr>
<tr>
<td>AI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.3</td>
<td>$35.00</td>
<td>$126.4K</td>
<td>367</td>
<td align="right">332</td>
</tr>
<tr>
<td>AI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$29.05</td>
<td>$28.35</td>
<td>$28.88</td>
<td>$10.00</td>
<td>$115.5K</td>
<td>436</td>
<td align="right">40</td>
</tr>
<tr>
<td>AI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$21.95</td>
<td>$21.4</td>
<td>$21.4</td>
<td>$20.00</td>
<td>$85.6K</td>
<td>1.3K</td>
<td align="right">145</td>
</tr>
<tr>
<td>AI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$21.55</td>
<td>$21.2</td>
<td>$21.2</td>
<td>$20.00</td>
<td>$80.5K</td>
<td>1.3K</td>
<td align="right">65</td>
</tr>
</tbody>
</table>
</p>
<h3>About C3.ai</h3>
<p>C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.</p>
<p>After a thorough review of the options trading surrounding C3.ai, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>C3.ai's Current Market Status</h3>
<ul>
<li>Trading volume stands at 5,276,663, with AI's price up by 5.29%, positioned at $39.4.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for C3.ai with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

C3.ai Unusual Options Activity

<p>Across the recent three months, 7 analysts have shared their insights on Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $304.57, a high estimate of $326.00, and a low estimate of $285.00. Marking an increase of 14.21%, the current average surpasses the previous average price target of $266.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732554034_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Manhattan Associates by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinton Gabrielli</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$326.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$305.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$304.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>George Kurosawa</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$287.00</td>
<td>$257.00</td>
</tr>
<tr>
<td>Mark Schappel</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Manhattan Associates. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Manhattan Associates compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Manhattan Associates's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Manhattan Associates's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MANH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Manhattan Associates analyst ratings.</strong></a></p>
<h2>About Manhattan Associates</h2>
<p>Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.</p>
<h3>Manhattan Associates: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Manhattan Associates's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>11.84%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Manhattan Associates's net margin excels beyond industry benchmarks, reaching <strong>23.92%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Manhattan Associates's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>24.6%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Manhattan Associates's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>9.36%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Manhattan Associates's debt-to-equity ratio is below the industry average at <strong>0.18</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MANH

Peeling Back The Layers: Exploring Manhattan Associates Through Analyst Insights

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Shopify</strong>.</p>
<p>Looking at options history for Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) we detected 44 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 52% of the investors opened trades with bullish expectations and 36% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $115,045 and 41, calls, for a total amount of $2,892,774.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $155.0 for Shopify, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Shopify's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Shopify's whale trades within a strike price range from $50.0 to $155.0 in the last 30 days. </p>
<h3>Shopify Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732554029_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$26.7</td>
<td>$26.5</td>
<td>$26.7</td>
<td>$105.00</td>
<td>$667.5K</td>
<td>3.4K</td>
<td>410</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$24.5</td>
<td>$23.9</td>
<td>$24.5</td>
<td>$90.00</td>
<td>$210.7K</td>
<td>2.0K</td>
<td>211</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$3.45</td>
<td>$3.3</td>
<td>$3.35</td>
<td>$110.00</td>
<td>$173.6K</td>
<td>1.5K</td>
<td>1.7K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.0</td>
<td>$2.95</td>
<td>$3.0</td>
<td>$120.00</td>
<td>$150.0K</td>
<td>6.1K</td>
<td>838</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$43.9</td>
<td>$43.25</td>
<td>$43.55</td>
<td>$90.00</td>
<td>$130.6K</td>
<td>459</td>
<td>30</td>
</tr>
</tbody>
</table>
</p>
<h3>About Shopify</h3>
<p>Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.</p>
<p>After a thorough review of the options trading surrounding Shopify, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Shopify Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,884,812, the price of SHOP is up by 3.17%, reaching $110.35.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 78 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Shopify</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $126.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Mizuho has decided to maintain their Neutral rating on Shopify, which currently sits at a price target of $105.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Shopify, which currently sits at a price target of $130.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Shopify, which currently sits at a price target of $130.<br />
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Shopify with a target price of $135.<br />
&#x2A; An analyst from Keybanc persists with their Overweight rating on Shopify, maintaining a target price of $130. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Shopify with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


SHOP

Shopify's Options: A Look at What the Big Money is Thinking

<p>High-rolling investors have positioned themselves bearish on Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in RCAT often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 17 options trades for Red Cat Hldgs. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 41% bullish and 52% bearish. Among all the options we identified, there was one put, amounting to $444,450, and 16 calls, totaling $1,566,550.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $15.0 for Red Cat Hldgs during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Red Cat Hldgs's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Red Cat Hldgs's substantial trades, within a strike price spectrum from $5.0 to $15.0 over the preceding 30 days.</p>
<h3>Red Cat Hldgs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732554024_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RCAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$9.0</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$15.00</td>
<td>$444.4K</td>
<td>0</td>
<td>505</td>
</tr>
<tr>
<td>RCAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.1</td>
<td>$2.75</td>
<td>$2.75</td>
<td>$7.00</td>
<td>$398.4K</td>
<td>4.6K</td>
<td>114</td>
</tr>
<tr>
<td>RCAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.1</td>
<td>$2.0</td>
<td>$2.09</td>
<td>$11.00</td>
<td>$168.9K</td>
<td>405</td>
<td>1.1K</td>
</tr>
<tr>
<td>RCAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.25</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$8.00</td>
<td>$133.1K</td>
<td>2.8K</td>
<td>525</td>
</tr>
<tr>
<td>RCAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.7</td>
<td>$1.4</td>
<td>$1.6</td>
<td>$10.00</td>
<td>$131.8K</td>
<td>1.5K</td>
<td>2.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Red Cat Hldgs</h3>
<p>Red Cat Holdings Inc is a military technology company that integrates robotic hardware and software to provide critical situational awareness and actionable intelligence to on-the-ground warfighters and battlefield commanders. Its mission is to enhance the effectiveness and safety of military operations domestically and globally. Red Cat's suite of solutions includes Teal Drones, developer of the Golden Eagle, a small unmanned system with the highest resolution imaging for night-time operations, and Skypersonic, a provider of unmanned aircraft for interior spaces and other dangerous environments.</p>
<p>In light of the recent options history for Red Cat Hldgs, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Red Cat Hldgs's Current Market Status</h3>
<ul>
<li>With a volume of 8,908,543, the price of RCAT is up 6.69% at $9.57. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 18 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Red Cat Hldgs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


RCAT

Unpacking the Latest Options Trading Trends in Red Cat Hldgs

<p>In the latest quarter, 9 analysts provided ratings for CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for CubeSmart, presenting an average target of $54.0, a high estimate of $62.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 2.62% from the previous average price target of $52.62.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732554019_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive CubeSmart is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Tricarico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$52.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jonathan Petersen</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$62.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$53.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$56.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CubeSmart. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CubeSmart compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for CubeSmart's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CubeSmart's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CUBE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on CubeSmart analyst ratings.</strong></a></p>
<h2>Delving into CubeSmart's Background</h2>
<p>CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.</p>
<h3>CubeSmart's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> CubeSmart's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>1.13%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>37.21%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> CubeSmart's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.63%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> CubeSmart's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.63%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.06</strong>, CubeSmart adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CUBE

The Latest Analyst Ratings For CubeSmart

<p>Ratings for Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $90.11, along with a high estimate of $120.00 and a low estimate of $70.00. Surpassing the previous average price target of $86.83, the current average has increased by 3.78%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732554010_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Block by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Alex Faure</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Vasundhara Govil</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$80.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Soomit Datta</td>
<td>New Street Research</td>
<td>Announces</td>
<td>Neutral</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Block. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Block compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Block's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Block's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SQ/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Block analyst ratings.</strong></a></p>
<h2>All You Need to Know About Block</h2>
<p>Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.</p>
<h3>Block's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Block's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>6.38%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Block's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>4.75%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Block's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.45%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.77%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.37</strong>, Block adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Block: Insights From 9 Financial Analysts

<p>Stifel  analyst W. Andrew Carter   maintains Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) with a Buy and raises the price target from $7 to $7.7.</p>


Stifel Maintains Buy on Latham Group, Raises Price Target to $7.7

<p><strong>Five Below Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) </strong>and other discount retailers were benefited by the Federal Reserve's <a href="https://www.benzinga.com/economics/24/09/41088930/what-does-a-rate-cut-mean-for-discount-retailers">interest rate cut in October</a>.</p>
<p>The company is currently undergoing a "major strategic transition across its business model" as well as leadership changes, according to Telsey Advisory Group.</p>
<p><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e301e08430dee0001c88c8d/joseph-feldman">Analyst Joseph Feldman</a> downgraded Five Below&#8217;s rating from Outperform to Sector Perform and reduced the price target from $102 to $95.</p>
<p><strong>The Five Below Thesis: </strong>The search for a permanent CEO is on, with <strong>Ken Bull</strong> having been named Interim CEO after the resignation of <strong>Joel Anderson</strong>, while SVP of General Merchandise <strong>Andy Kunselman</strong> has replaced retiring Chief Merchant <strong>Michael Romanko</strong>, Feldman said in the downgrade note.</p>
<p><strong>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.</strong></p>
<p>"The company dealt with the last round of tariffs by breaking the $5 price point and gradually increasing prices since then, while quality did not always keep pace, thereby eroding value," the analyst wrote.</p>
<p>He stated that Five Below has begun to focus on recapturing its value proposition in merchandising, reducing the number of price points to simplify execution, and adding more value to products.</p>
<p>The impact of new merchandising is likely to be more visible in the back half of 2025, Feldman said. Five Below's strategic transition, leadership changes and potential tariffs clouds visibility into 2025 and beyond, he added.</p>
<p><strong>FIVE Price Action:</strong> Shares of Five Below were up 8.2% to $94.19 at the time of publication on Monday.</p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/24/11/42017468/4-stocks-to-sell-before-trumps-tariffs-take-effect">4 Stocks to Sell Before Trump&#8217;s Tariffs Take Effect</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

FIVE

Five Below Analyst Warns Of 'Eroding Value' As 'Quality Did Not Always Keep Pace'

<p>Stifel  analyst Stephen Gengaro   maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Buy and raises the price target from $45 to $48.</p>


Stifel Maintains Buy on Baker Hughes, Raises Price Target to $48

<p>Vertically integrated cannabis producer <strong>Cannara Biotech Inc</strong>. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#TSXV">LOVE</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/LOVFF#OTCQB">LOVFF</a>) (FRA: 8CB0) announced its fourth quarter and full fiscal 2024 financial and operating results on Monday ended Aug. 31.</p>
<p>The Montreal-based company revealed a 43% year-over-year revenue growth in 2024 to CA$82.2 million ($58.8 million).</p>
<p>Gross profit for the full year grew by 32% over the same period, reaching CA$27.9 million, with a gross margin of 34% before fair value adjustments.</p>
<p>Positive operating cash flow increased by 81% to CA$10.7 million, while free cash flow turned positive at CA$3.2 million, a CA$7.2 million turnaround from 2023.</p>
<p>"Fiscal 2024 was a transformative year for Cannara, showcasing the resilience of our business model and the strength of our execution strategy," said <strong>Zohar Krivorot, </strong>president and CEO. "With a 3.2% national market share and a leading position in Québec, we have proven our ability to deliver sustained growth in a challenging cannabis market. By investing in our state-of-the-art production facilities, powered by the lowest-cost electricity in the country, we continue to produce premium cannabis products at an unmatched value."</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/39914893/cannara-biotech-reports-6-yoy-drop-in-q3-gross-profit-22-revenue-increase-as-it-enhances-sales-f">Cannara Biotech Reports 6% YoY Drop In Q3 Gross Profit, 22% Revenue Increase As It Enhances Sales Force And Infrastructure</a></strong> </p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</em></strong></li>
</ul>
<h3 class="wp-block-heading">Q4 2024 Financial Highlights</h3>
<ul>
<li>Revenue saw a 28% increase year-over-year, totaling CA$23.4 million.</li>
<li>Gross profit before fair value adjustments was CA$7 million, a 2% year-over-year increase. The gross profit percentage before fair value adjustments was 30%. Gross profit after fair value adjustments was 46%.</li>
<li>Operating income was CA$5 million, compared to operating income of CA$5.8 million in the same quarter of 2023.</li>
<li>Adjusted EBITDA came in positive at CA$3.7 million or 16% of net revenues compared to an adjusted EBITDA gain of CA$4.9 million in the same period of the prior year.</li>
<li>Net income totaled CA$5.8 million compared to CA$ 4.6 million in the prior year's period.</li>
<li>Positive operating cash flows of CA$3.2 million, compared to CA$2.9 million in the same period of fiscal 2023.</li>
<li>Free cash flow increased to CA$2.7 million from CA$1.1 million in the fourth quarter of 2023, representing a year-over-year increase of 143%.</li>
</ul>
<h3 class="wp-block-heading">FY 2024 Financial Highlights</h3>
<ul>
<li>Operating income was CA$10.1 million, compared to operating income of CA$11.9 million for 2023.</li>
<li>Adjusted EBITDA amounted to CA$15.1 million, representing a 10% increase compared to the prior year.</li>
<li>Net income was CA$6.4 million, compared to CA$6.9 million in 2023.</li>
<li>The company's national market share rose to 3.2% in the fourth quarter, up from 2.3% in the same period of 2023.</li>
<li>Cannara also saw strong growth in Québec, with market share increasing to 12.6% in October.</li>
</ul>
<h3 class="wp-block-heading">Outlook</h3>
<p>Cannara reported that it plans to launch over 20 new products in fiscal 2025, with innovative formats like all-in-one vape devices and premium infused pre-rolls.</p>
<p>For fiscal 2025, the company aims to activate two more zones, adding 50,000 sq. ft. of active canopy, while its 24-zone facility allows scalable production in lockstep with demand.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/05/38563458/cannara-biotech-reports-51-yoy-revenue-increase-in-q2-wider-net-loss"><strong>Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss</strong></a></li>
</ul>


Cannabis

LOVE

LOVFF

TSXV:LOVE

Canadian Cannabis Producer Cannara Reports 43% YoY Revenue Growth, Boosts Market Share And Profitability

Macro Economic Events

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid a drop in Treasury yields.

Bausch Health Companies (TSE:BHC) has released an update. Bausch Health Companies reported a strong third quarter of 2024, achieving a 12% increase...

Bausch Health Reports Strong Growth in Q3 2024

Bausch Health Companies GAAP EPS of -$0.23 misses by $0.37, revenue of $2.51B beats by $90M

Bausch Health raises 2024 revenue guidance

Bausch Health Companies Inc. 2024 Q3 - Results - Earnings Call Presentation

Bausch Health Companies ( ($BHC) ) has realeased its Q3 earnings. Here is a breakdown of the information Bausch Health Companies presented to its i...

Bausch Health Reports Growth Amid Improved Financials

Truist Financial analyst Les Sulewski maintained a Hold rating on Bausch Health Companies (BHC – Research Report) today and set a price target of $...

Truist Financial Keeps Their Hold Rating on Bausch Health Companies (BHC)

Steve Scala, an analyst from TD Cowen, maintained the Hold rating on Bausch Health Companies (BHC – Research Report). The associated price target i...

Bausch Health Companies: Hold Rating Amid Mixed Financial Performance and Strategic Uncertainty

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly exploring a potential sale in ...

Bausch + Lomb (BLCO) Posts Impressive Revenue and Explores Potential Sale

Bausch Health (BHC) Companiesannounced the first look at its late-stage RED-C clinical trial program which will be presented at the American Associ...

Bausch Health, Salix to present RED-C Phase 3 study design

Bausch Health (BHC) announced that CABTREO gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical prescription treatment for acne v...

Bausch Health announces CABTREO receives positive reimbursement recommendations

BLCO

Management

Press Releases

Bausch Health Welcomes Two New Members to the Executive Leadership Team

Bausch Health Responds to Market Rumors

Earnings

Bausch Health Announces Second Quarter 2024 Results

Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older

Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

Events

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Bausch Health Announces Third Quarter 2024 Results

Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis

PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS

Comments

Bausch Health Companies

Vendite allo scoperto

Bausch Health Companies (NYSE:BHC) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO